Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferreri, A.J.M.
Right arrow Articles by Reni, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreri, A.J.M.
Right arrow Articles by Reni, M.
Related Collections
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
Right arrow Radiation therapy-tumor
NEUROLOGY 2006;66:1435-1438
© 2006 American Academy of Neurology
Brief Communications

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

A.J.M. Ferreri, MD, S. Dell’Oro, MD, M. Foppoli, MD, M. Bernardi, MD, A. A. Brandes, MD, A. Tosoni, MD, M. Montanari, MD, M. Balzarotti, MD, M. Spina, MD, F. Ilariucci, MD, F. Zaja, MD, C. Stelitano, MD, F. Bobbio, MD, G. Corazzelli, MD, L. Baldini, MD, M. Ponzoni, MD, P. Picozzi, MD, F. Caligaris Cappio, MD and M. Reni, MD

From the Medical Oncology Unit (A.J.M.F., S.D., M.R.), Internal Medicine Unit (M.F., F.C.C.), UTMO and Hematology Unit, Department of Oncology (M. Bernardi), Pathology Unit (M.P.), and Neurosurgery Unit (P.P.), San Raffaele H Scientific Institute and Università Vita-Salute San Raffaele, Milan; Neuro-Oncology Unit (A.A.B., A.T.), Azienda Ospedaliera di Padova, Padova; Division of Hematology (M.M.), Osp. di Ancona, Ancona; Department of Medical Oncology and Hematology (M. Balzarotti), Istituto Clinico Humanitas, Rozzano; Division of Medical Oncology A (M.S.), National Cancer Institute, Aviano; Division of Hematology (F.I.), Osp. di Reggio Emilia, Reggio Emilia; Division of Hematology (F.Z.), Osp. di Udine, Udine; Division of Hematology (C.S.), Osp. di Reggio Calabria, Reggio Calabria; Division of Hematology (F.B.), Osp. Maggiore di Novara, Novara; Division of Hematology (G.C.), Istituto Nazionale dei Tumori Pascale di Napoli; and Division of Hematology (L.B.), Osp. Maggiore di Milano, Milan, Italy.

Address correspondence and reprint requests to Dr. Andrés J.M. Ferreri, Medical Oncology Unit, Department of Oncology, San Raffaele H Scientific Institute, Via Olgettina 60, 20132–Milan, Italy; e-mail: ferreri.andres{at}hsr.it

The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the May 9 issue to find the title link for this article.

Disclosure: The authors report no conflicts of interest.

Received October 9, 2005. Accepted in final form January 19, 2006.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan
Primary CNS Lymphoma in Immunocompetent Patients
Oncologist, May 1, 2009; 14(5): 526 - 539.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. D. Shah, J. Yahalom, D. D. Correa, R. K. Lai, J. J. Raizer, D. Schiff, R. LaRocca, B. Grant, L. M. DeAngelis, and L. E. Abrey
Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma
J. Clin. Oncol., October 20, 2007; 25(30): 4730 - 4735.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. M. Ferreri, M. Reni, E. Zucca, and F. Cavalli
Primary CNS Lymphomas Prognosis
J. Clin. Oncol., September 20, 2007; 25(27): 4322 - 4324.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.